What Is Semaglutide?
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a hormone produced by L-cells in the small intestine in response to food intake. The peptide shares 94% structural homology with native GLP-1 but has been engineered with key modifications — including a C-18 fatty acid chain and amino acid substitutions — that extend its half-life from approximately 2 minutes to roughly 7 days, enabling once-weekly dosing.[1]
It was first approved by the FDA in 2017 as Ozempic for type 2 diabetes management, followed by Wegovy in 2021 for chronic weight management. An oral formulation, Rybelsus, was approved in 2019 for diabetes, making semaglutide the first GLP-1 receptor agonist available in pill form.
Mechanism of Action
Semaglutide works through multiple complementary pathways:
- Appetite suppression: Activates GLP-1 receptors in the hypothalamus and brainstem, particularly the arcuate nucleus, reducing hunger signaling and increasing satiety.
- Delayed gastric emptying: Slows the rate at which food moves from the stomach into the small intestine, promoting prolonged fullness after meals.
- Glucose-dependent insulin secretion: Enhances insulin release from pancreatic beta cells only when blood glucose is elevated, reducing hypoglycemia risk compared to older diabetes medications.
- Glucagon suppression: Reduces glucagon secretion from alpha cells during hyperglycemia, lowering hepatic glucose output.
- Central reward modulation: Emerging research suggests GLP-1 receptor activation in the mesolimbic system may reduce food reward and cravings, potentially explaining effects beyond simple appetite reduction.[2]
Clinical Trial Data
Semaglutide has one of the most extensive clinical evidence bases of any weight management drug, primarily through the STEP (Semaglutide Treatment Effect in People with Obesity) trial program.
STEP Trial Program — Key Results
| Trial | Population | Duration | Avg. Weight Loss | Key Finding |
|---|---|---|---|---|
| STEP 1 | Obesity without T2D (n=1,961) | 68 weeks | −14.9% | 86.4% achieved ≥5% weight loss |
| STEP 2 | Obesity with T2D (n=1,210) | 68 weeks | −9.6% | Significant HbA1c improvements |
| STEP 3 | Obesity + intensive behavioral therapy | 68 weeks | −16.0% | Enhanced outcomes with lifestyle intervention |
| STEP 5 | Long-term treatment (n=304) | 104 weeks | −15.2% | Sustained weight loss over 2 years |
| STEP UP | Obesity without T2D (7.2 mg dose) | 72 weeks | −20.7% | 33% achieved ≥25% weight loss |
All trials used semaglutide 2.4 mg once weekly (the Wegovy dose) unless otherwise noted. Weight loss was measured versus placebo, with all participants receiving lifestyle counseling.[3][4]
SELECT Trial — Cardiovascular Benefit: The SELECT cardiovascular outcomes trial demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with obesity and established cardiovascular disease, even without diabetes. This was the first obesity medication to show a direct cardiovascular mortality benefit.[5]
Weight Regain After Discontinuation
The STEP 1 extension study showed that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within one year of discontinuation (mean net weight loss dropped from −17.3% to −5.6%). This underscores that semaglutide treats obesity as a chronic condition — sustained use is typically required to maintain results.[6]
Head-to-Head vs. Tirzepatide (SURMOUNT-5)
In the first direct clinical comparison, the SURMOUNT-5 trial showed that tirzepatide produced greater weight loss than semaglutide at maximum tolerated doses: −20.2% vs. −13.7% over 72 weeks. However, semaglutide has a longer safety track record and additional cardiovascular outcome data that tirzepatide does not yet have.[7]
Side Effects & Safety
Common Side Effects
Gastrointestinal effects are the most frequently reported and tend to be most pronounced during dose escalation:
- Nausea — 39–44% of patients (vs. ~16% placebo)
- Diarrhea — 29–30%
- Vomiting — 24–25%
- Constipation — 23–24%
- Abdominal pain — 18–20%
Most GI symptoms are mild to moderate and diminish within 4–8 weeks as patients titrate to their maintenance dose. The STEP 5 trial reported 82.2% of semaglutide participants experienced at least one GI adverse event over two years, compared to 53.9% on placebo.[4]
Serious Risks & Warnings
⚠️ Boxed Warning — Thyroid C-Cell Tumors
In rodent studies, semaglutide caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether semaglutide causes thyroid C-cell tumors in humans. Semaglutide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Other serious but uncommon risks include:
- Pancreatitis: Acute pancreatitis has been reported. Discontinue promptly if suspected.
- Gallbladder disease: Increased risk of cholelithiasis (gallstones) associated with rapid weight loss.
- Hypoglycemia: Risk increases when combined with insulin or sulfonylureas.
- Acute kidney injury: Reported in patients with dehydration from severe GI adverse events.
- Suicidal ideation: The FDA has investigated post-marketing reports; data remains inconclusive as of 2026.
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide or excipients
- Pregnancy (Category X — contraindicated; discontinue at least 2 months before planned conception)
Dosing Context
Semaglutide dosing follows a slow escalation schedule to minimize GI side effects. The following reflects FDA-approved prescribing information — actual dosing should always be determined by a licensed healthcare provider.
Wegovy (Weight Management) — FDA-Approved Schedule
| Weeks | Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg | Initiation |
| Weeks 5–8 | 0.5 mg | Escalation |
| Weeks 9–12 | 1.0 mg | Escalation |
| Weeks 13–16 | 1.7 mg | Escalation |
| Week 17+ | 2.4 mg | Maintenance |
Administered via subcutaneous injection in the abdomen, thigh, or upper arm. Injection site should be rotated weekly. If a dose is missed, administer within 5 days; otherwise skip and resume the next scheduled dose.
Legal & Regulatory Status (2026)
The regulatory landscape for semaglutide is currently in flux, particularly around compounding:
FDA-Approved Products
Brand-name semaglutide (Ozempic, Wegovy, Rybelsus) is fully FDA-approved and available by prescription through standard pharmacies. No generic versions exist yet — Novo Nordisk holds patent protection.
Compounding Status
Semaglutide's compounding situation has evolved rapidly:
- Shortage list: Semaglutide was added to the FDA drug shortage list in 2022 and removed in February 2025 as supply stabilized.
- 503B Bulks List: On April 30, 2026, the FDA proposed excluding semaglutide (along with tirzepatide and liraglutide) from the 503B Bulks List, finding no clinical need for outsourcing facility compounding. The public comment period closes June 29, 2026.
- 503A pharmacies: Patient-specific compounding by state-licensed 503A pharmacies operates under a different legal framework and continues, though the FDA has increased scrutiny — including warning letters to pharmacies suggesting equivalence with FDA-approved products.
- Litigation: Multiple court cases between compounding industry groups and the FDA have created legal uncertainty. Injunctions currently prevent complete enforcement shutdowns in some jurisdictions.
⚠️ Compounding Safety Concerns
The FDA has received over 455 adverse event reports linked to compounded semaglutide, many involving dosing errors from patients self-administering incorrect doses from multidose vials. Only purchase compounded peptides from verified, state-licensed pharmacies with third-party testing documentation.
Research Peptides
Semaglutide is available as a research compound from specialized peptide suppliers. Research peptides are sold for laboratory and investigational use only — not for human consumption. Researchers should verify purity through independent certificates of analysis (COAs) and ensure compliance with all applicable regulations.
Frequently Asked Questions
How is semaglutide different from tirzepatide?
Semaglutide targets only the GLP-1 receptor, while tirzepatide is a dual GLP-1/GIP receptor agonist. In head-to-head trials, tirzepatide showed greater weight loss (−20.2% vs. −13.7%), but semaglutide has longer-term safety data and cardiovascular outcome evidence from the SELECT trial.
How long does it take to see results?
Most patients notice reduced appetite within the first 1–2 weeks. Clinically meaningful weight loss (≥5%) is typically achieved by weeks 12–16. Maximum weight loss generally plateaus around weeks 60–68 at the maintenance dose.
Can you take semaglutide long-term?
Yes — the STEP 5 trial demonstrated sustained efficacy and safety over 104 weeks. Current clinical guidance treats obesity as a chronic disease requiring ongoing management. Discontinuation typically leads to weight regain.
Does semaglutide cause muscle loss?
Some lean mass loss occurs with any significant weight reduction. In the STEP trials, approximately 25–40% of total weight lost was lean mass. Resistance training and adequate protein intake (1.2–1.6 g/kg/day) are recommended to minimize muscle loss during treatment.
References
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PubMed
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: STEP 5 Trial. Nat Med. 2022;28:2083-2091. PubMed
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed
- Wilding JPH, Batterham RL, Davies M, et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: STEP 1 Extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed
- Aronne LJ, et al. Tirzepatide vs. Semaglutide in Adults with Obesity (SURMOUNT-5). N Engl J Med. 2025. PubMed
- FDA. Proposal to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List. Federal Register. April 30, 2026. FDA.gov